Alzheimer’s and brain imaging
Executive Summary
The role of brain imaging as an outcome measure in Phase III Alzheimer's Disease trials will be discussed at a joint meeting of FDA's Peripheral & Central Nervous System Drugs and Medical Imaging Drugs Advisory Committees Nov. 18. On Nov. 19, the committees will review Down State Medical's positron emission tomography agent F18 fluoro-D-glucose for imaging in Alzheimer's Disease. The meeting will take place at the Holiday Inn, Gaithersburg, Md...
You may also be interested in...
Down State Medical F18 FDG review cancelled
A Nov. 19 review of Down State Medical's positron emission tomography agent F18 fluoro-D-glucose (FDG) for the diagnosis and/or identification of Alzheimer's disease progression has been cancelled. FDA's Peripheral & Central Nervous System Drugs Committee still will discuss the use of Alzheimer's brain imaging as a surrogate endpoint in clinical trials on Nov. 18 (1"The Pink Sheet" Sept. 30, In Brief)...
Abbott Launches Five-Minute POC Rapid COVID-19 Test
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: